A G Tos
Overview
Explore the profile of A G Tos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foa R, Tos A, Francia di Celle P, Carbone A, Marchis D, Vischia F, et al.
Leuk Lymphoma
. 2016 Jul;
5 Suppl 1:7-11.
PMID: 27463473
The pleomorphic action of different cytokines in regulating the growth and proliferation of normal B- and T-lymphocyte populations is becoming progressively more apparent. Thus, the possibility that some cytokines, either...
2.
Bellone G, Fierro M, Liao X, Tos A, Bonferroni M, Pegoraro L, et al.
Leuk Lymphoma
. 2010 Apr;
1(5-6):341-52.
PMID: 20394563
Adoptive immunotherapy with lymphokine-activated killer (LAK) cells induced by Interleukin 2 (IL2) has provided a new and promising strategy for the treatment of cancer patients. The clinical observation of variable...
3.
Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, et al.
Blood
. 1994 Oct;
84(7):2158-63.
PMID: 7919330
The administration of interleukin-2 (IL-2) may induce complete remissions in acute myelogenous leukemia (AML) patients with a low proportion of residual bone marrow (BM) blasts. To confirm this preliminary observation,...
4.
Foa R, Meloni G, Guarini A, Vignetti M, Marchis D, Tosti S, et al.
Leukemia
. 1992 Jan;
6 Suppl 3:115S-116S.
PMID: 1602806
In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible...
5.
Foa R, Fierro M, Raspadori D, Bonferroni M, Cardona S, Guarini A, et al.
Blood
. 1990 Oct;
76(7):1349-54.
PMID: 2207312
The capacity to generate lymphokine-activated killer (LAK) cells and the susceptibility of the neoplastic cells to both allogeneic and autologous LAK effectors were studied in B and T chronic lymphoproliferative...
6.
Foa R, Massaia M, Cardona S, Tos A, Bianchi A, Attisano C, et al.
Blood
. 1990 Jul;
76(2):393-400.
PMID: 2114936
Tumor necrosis factor-alpha (TNF) is a cytokine that displays a pleomorphic array of effects on different cell populations. Evidence is presented that TNF may be constitutively produced by B-cell chronic...